These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 20839259)

  • 1. Sorafenib reduces the percentage of tumour infiltrating regulatory T cells in renal cell carcinoma patients.
    Desar IM; Jacobs JH; Hulsbergen-vandeKaa CA; Oyen WJ; Mulders PF; van der Graaf WT; Adema GJ; van Herpen CM; de Vries IJ
    Int J Cancer; 2011 Jul; 129(2):507-12. PubMed ID: 20839259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sorafenib, but not sunitinib, induces regulatory T cells in the peripheral blood of patients with metastatic renal cell carcinoma.
    Flörcken A; Takvorian A; Van Lessen A; Singh A; Hopfenmüller W; Dörken B; Pezzutto A; Westermann J
    Anticancer Drugs; 2012 Mar; 23(3):298-302. PubMed ID: 22156795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Application monitoring of the use of sorafenib in papillary renal cell carcinoma].
    Schrader AJ; Hegele A; Olbert P; Buer J; Jeron A; Hofmann R
    Urologe A; 2007 Sep; 46(9):1291. PubMed ID: 17668165
    [No Abstract]   [Full Text] [Related]  

  • 4. Sorafenib in renal cell carcinoma.
    Arranz JÁ; Climent MÁ; González-Larriba JL; León L; Maroto JP
    Crit Rev Oncol Hematol; 2011 Nov; 80(2):314-22. PubMed ID: 21419641
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sorafenib relieves cell-intrinsic and cell-extrinsic inhibitions of effector T cells in tumor microenvironment to augment antitumor immunity.
    Chen ML; Yan BS; Lu WC; Chen MH; Yu SL; Yang PC; Cheng AL
    Int J Cancer; 2014 Jan; 134(2):319-31. PubMed ID: 23818246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GSK-3 inhibition in vitro and in vivo enhances antitumor effect of sorafenib in renal cell carcinoma (RCC).
    Kawazoe H; Bilim VN; Ugolkov AV; Yuuki K; Naito S; Nagaoka A; Kato T; Tomita Y
    Biochem Biophys Res Commun; 2012 Jul; 423(3):490-5. PubMed ID: 22683636
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sorafenib [corrected] in kidney cancer.
    Escudier B
    Ann Oncol; 2007 Jul; 18 Suppl 9():ix90-3. PubMed ID: 17631603
    [No Abstract]   [Full Text] [Related]  

  • 8. Sorafenib for the management of advanced renal cell carcinoma.
    Escudier B
    Expert Rev Anticancer Ther; 2011 Jun; 11(6):825-36. PubMed ID: 21707277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor-infiltrating regulatory T cells are positively correlated with angiogenic status in renal cell carcinoma.
    Ning H; Shao QQ; Ding KJ; Gao DX; Lu QL; Cao QW; Niu ZH; Fu Q; Zhang CH; Qu X; Lü JJ
    Chin Med J (Engl); 2012 Jun; 125(12):2120-5. PubMed ID: 22884140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigm.
    Shuch B; Riggs SB; LaRochelle JC; Kabbinavar FF; Avakian R; Pantuck AJ; Patard JJ; Belldegrun AS
    BJU Int; 2008 Sep; 102(6):692-6. PubMed ID: 18410444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic immune tuning in renal cell carcinoma: favorable prognostic impact of TGF-β1 mRNA expression in peripheral blood mononuclear cells.
    Busse A; Asemissen A; Nonnenmacher A; Ochsenreither S; Fusi A; Braun F; Stather D; Schmittel A; Miller K; Thiel E; Keilholz U
    J Immunother; 2011 Jan; 34(1):113-9. PubMed ID: 21150720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sorafenib.
    Hasskarl J
    Recent Results Cancer Res; 2010; 184():61-70. PubMed ID: 20072831
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sorafenib: scientific rationales for single-agent and combination therapy in clear-cell renal cell carcinoma.
    Gollob JA
    Clin Genitourin Cancer; 2005 Dec; 4(3):167-74. PubMed ID: 16425993
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protein kinase inhibitors in the treatment of renal cell carcinoma: sorafenib.
    Bracarda S; Caserta C; Sordini L; Rossi M; Hamzay A; Crinò L
    Ann Oncol; 2007 Jun; 18 Suppl 6():vi22-5. PubMed ID: 17591826
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Myocardial metastasis from renal cell carcinoma treated with sorafenib].
    Tokuyama Y; Iwamura M; Fujita T; Sugita A; Maeyama R; Bessho H; Ishikawa W; Tabata K; Yoshida K; Baba S
    Hinyokika Kiyo; 2011 Oct; 57(10):555-8. PubMed ID: 22089153
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response to sorafenib in a patient with metastatic xp11 translocation renal cell carcinoma.
    Hou MM; Hsieh JJ; Chang NJ; Huang HY; Wang HM; Chuang CK; Hsu T; Chang JW
    Clin Drug Investig; 2010; 30(11):799-804. PubMed ID: 20635828
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunomodulatory effects of sorafenib on peripheral immune effector cells in metastatic renal cell carcinoma.
    Busse A; Asemissen AM; Nonnenmacher A; Braun F; Ochsenreither S; Stather D; Fusi A; Schmittel A; Miller K; Thiel E; Keilholz U
    Eur J Cancer; 2011 Mar; 47(5):690-6. PubMed ID: 21215610
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tyrosine kinase inhibitor sorafenib decreases 111In-girentuximab uptake in patients with clear cell renal cell carcinoma.
    Muselaers CH; Stillebroer AB; Desar IM; Boers-Sonderen MJ; van Herpen CM; de Weijert MC; Langenhuijsen JF; Oosterwijk E; Leenders WP; Boerman OC; Mulders PF; Oyen WJ
    J Nucl Med; 2014 Feb; 55(2):242-7. PubMed ID: 24396030
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of sorafenib treatment on the diabetic status of patients with renal cell or hepatocellular carcinoma.
    Imarisio I; Paglino C; Ganini C; Magnani L; Caccialanza R; Porta C
    Future Oncol; 2012 Aug; 8(8):1051-7. PubMed ID: 22894676
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America.
    Stadler WM; Figlin RA; McDermott DF; Dutcher JP; Knox JJ; Miller WH; Hainsworth JD; Henderson CA; George JR; Hajdenberg J; Kindwall-Keller TL; Ernstoff MS; Drabkin HA; Curti BD; Chu L; Ryan CW; Hotte SJ; Xia C; Cupit L; Bukowski RM;
    Cancer; 2010 Mar; 116(5):1272-80. PubMed ID: 20082451
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.